GLAXOSMITHKLINE PLC Form 6-K May 15, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 15 May 2018

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company') Transaction notification

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Mr P Thomson
	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
	Details of the transaction(s): section to be repeated for (i) each type of	
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each	
	place where transaction(s) has been conducted	
		Ordinary shares of 25 pence each ('Ordinary Shares')
a)	Description of the financial instrument	ISIN: GB0009252882
b)	Nature of the transaction	Sale of Ordinary Shares.
c)	Price(s) and volume(s)	Price(s) Volume(s) £14.6967 65,000
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2018-05-15
n.	Place of the transaction	London Stock Exchange
f)		

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

(XLON)

GlaxoSmithKline plc (Registrant)

Date: May 15, 2018

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc